Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021
<strong>Foundation</strong>: SARS-CoV-2 infection is the most important emerging disease of this century. In this context, the Cuban Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) created therapeutic alternatives to combat COVID-19, including the use of Jusvinza, which...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Centro Provincial de Información de Ciencias Médicas. Cienfuegos
2024-01-01
|
| Series: | Medisur |
| Subjects: | |
| Online Access: | http://medisur.sld.cu/index.php/medisur/article/view/45089 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576870310215680 |
|---|---|
| author | Sandra Caridad Laurencio Vallina Martha María Arias Carbonell Leonardo Ramos Hechavarría Dayami Lescay Balanquet Roger Pina Núñez |
| author_facet | Sandra Caridad Laurencio Vallina Martha María Arias Carbonell Leonardo Ramos Hechavarría Dayami Lescay Balanquet Roger Pina Núñez |
| author_sort | Sandra Caridad Laurencio Vallina |
| collection | DOAJ |
| description | <strong>Foundation</strong>: SARS-CoV-2 infection is the most important emerging disease of this century. In this context, the Cuban Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) created therapeutic alternatives to combat COVID-19, including the use of Jusvinza, which is part of the protocol used in the country. <br /><strong>Objective</strong>: to determine the Jusvinza therapeutic resolution in confirmed COVID-19 patients. <br /><strong>Methods</strong>: a descriptive study carried out from January to September 2021, at the Dr. Joaquín Castillo Duany Military Hospital, in Santiago de Cuba. The universe consisted of 166 confirmed COVID-19 cases, to whom Jusvinza was administered. Some clinical variables (clinical status, associated non-communicable diseases, clinical progression), epidemiological (age, sex) and pharmacological (resolving, duration in days) were analyzed. A data extraction form was used, which was taken from the medical records. <br /><strong>Results</strong>: morbidity and mortality from COVID-19 was higher in males, related to comorbidities and age over 60 years; The female sex was the one with the greatest response to treatment with Jusvinza (71.7%), which increased its percentage in the absence of associated chronic non-communicable diseases (81.4%). High-risk patients had the lowest mortality (15.8%). <br /><strong>Conclusions</strong>: resolution in confirmed COVID-19 patients treated with Jusvinza was higher in high-risk cases than in severe and critical cases. |
| format | Article |
| id | doaj-art-f93995219a6041a2a9193939f3c95718 |
| institution | Kabale University |
| issn | 1727-897X |
| language | Spanish |
| publishDate | 2024-01-01 |
| publisher | Centro Provincial de Información de Ciencias Médicas. Cienfuegos |
| record_format | Article |
| series | Medisur |
| spelling | doaj-art-f93995219a6041a2a9193939f3c957182025-01-30T21:29:02ZspaCentro Provincial de Información de Ciencias Médicas. CienfuegosMedisur1727-897X2024-01-012211201262469Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021Sandra Caridad Laurencio Vallina0Martha María Arias Carbonell1Leonardo Ramos Hechavarría2Dayami Lescay Balanquet3Roger Pina Núñez4Hospital Militar Dr. Joaquín Castillo Duany. Santiago de CubaHospital Militar Dr. Joaquín Castillo Duany. Santiago de CubaHospital Militar Dr. Joaquín Castillo Duany. Santiago de CubaHospital Militar Dr. Joaquín Castillo Duany. Santiago de CubaHospital Militar Dr. Joaquín Castillo Duany. Santiago de Cuba<strong>Foundation</strong>: SARS-CoV-2 infection is the most important emerging disease of this century. In this context, the Cuban Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) created therapeutic alternatives to combat COVID-19, including the use of Jusvinza, which is part of the protocol used in the country. <br /><strong>Objective</strong>: to determine the Jusvinza therapeutic resolution in confirmed COVID-19 patients. <br /><strong>Methods</strong>: a descriptive study carried out from January to September 2021, at the Dr. Joaquín Castillo Duany Military Hospital, in Santiago de Cuba. The universe consisted of 166 confirmed COVID-19 cases, to whom Jusvinza was administered. Some clinical variables (clinical status, associated non-communicable diseases, clinical progression), epidemiological (age, sex) and pharmacological (resolving, duration in days) were analyzed. A data extraction form was used, which was taken from the medical records. <br /><strong>Results</strong>: morbidity and mortality from COVID-19 was higher in males, related to comorbidities and age over 60 years; The female sex was the one with the greatest response to treatment with Jusvinza (71.7%), which increased its percentage in the absence of associated chronic non-communicable diseases (81.4%). High-risk patients had the lowest mortality (15.8%). <br /><strong>Conclusions</strong>: resolution in confirmed COVID-19 patients treated with Jusvinza was higher in high-risk cases than in severe and critical cases.http://medisur.sld.cu/index.php/medisur/article/view/45089infecciones por coronavirusfactores inmunitariosmorbilidadmortalidadresultado del tratamiento |
| spellingShingle | Sandra Caridad Laurencio Vallina Martha María Arias Carbonell Leonardo Ramos Hechavarría Dayami Lescay Balanquet Roger Pina Núñez Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021 Medisur infecciones por coronavirus factores inmunitarios morbilidad mortalidad resultado del tratamiento |
| title | Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021 |
| title_full | Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021 |
| title_fullStr | Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021 |
| title_full_unstemmed | Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021 |
| title_short | Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021 |
| title_sort | jusvinza treatment resolution in confirmed covid 19 patients santiago de cuba 2021 |
| topic | infecciones por coronavirus factores inmunitarios morbilidad mortalidad resultado del tratamiento |
| url | http://medisur.sld.cu/index.php/medisur/article/view/45089 |
| work_keys_str_mv | AT sandracaridadlaurenciovallina jusvinzatreatmentresolutioninconfirmedcovid19patientssantiagodecuba2021 AT marthamariaariascarbonell jusvinzatreatmentresolutioninconfirmedcovid19patientssantiagodecuba2021 AT leonardoramoshechavarria jusvinzatreatmentresolutioninconfirmedcovid19patientssantiagodecuba2021 AT dayamilescaybalanquet jusvinzatreatmentresolutioninconfirmedcovid19patientssantiagodecuba2021 AT rogerpinanunez jusvinzatreatmentresolutioninconfirmedcovid19patientssantiagodecuba2021 |